MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

Search

Maravai LifeSciences Holdings Inc (Class A)

Closed

SectorHealthcare

2.95 2.43

Overview

Share price change

24h

Current

Min

2.91

Max

2.95

Key metrics

By Trading Economics

Income

-15M

-40M

Sales

8.2M

50M

Profit margin

-80.43

Employees

435

EBITDA

-19M

-42M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+39.37% upside

Dividends

By Dow Jones

Next Earnings

11 maj 2026

Market Stats

By TradingEconomics

Market Cap

-62M

1.1B

Previous open

0.52

Previous close

2.95

News Sentiment

By Acuity

50%

50%

166 / 349 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

3 kwi 2026, 04:27 UTC

Major News Events

Singapore PM Warns That Fallout From Mideast War Could Outlast Conflict

3 kwi 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3 kwi 2026, 18:30 UTC

Major News Events

An F15-E Just Went Down in Iran. What to Know About the $30 Million Jet. -- Barrons.com

3 kwi 2026, 18:14 UTC

Market Talk

Eli Lilly Seen as Possible GLP-1 Leader With New Pill Approval -- Market Talk

3 kwi 2026, 17:50 UTC

Market Talk

Microsoft's AI Development Will Weigh on Near-Term Azure Growth -- Market Talk

3 kwi 2026, 17:44 UTC

Acquisitions, Mergers, Takeovers

SBA Stock Just Had a Big Day. Why It's Suddenly Hot. -- Barrons.com

3 kwi 2026, 16:50 UTC

Major News Events

An F15-E Just Went Down in Iran. What to Know About the $90 Million Jet. -- Barrons.com

3 kwi 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3 kwi 2026, 16:12 UTC

Earnings

Oil Stocks Look Tapped Out. Why It's Time to Move Into Other Sectors. -- Barrons.com

3 kwi 2026, 15:56 UTC

Market Talk
Major News Events

Crypto Markets May Be Active Over Holiday Weekend -- Market Talk

3 kwi 2026, 15:56 UTC

Market Talk
Major News Events

Global Equities Roundup: Market Talk

3 kwi 2026, 15:56 UTC

Market Talk
Major News Events

Global Forex and Fixed Income Roundup: Market Talk

3 kwi 2026, 15:20 UTC

Major News Events

Berkshire, Travelers Join U.S. Plan to Insure Shippers in the Hormuz Strait -- Barrons.com

3 kwi 2026, 15:08 UTC

Acquisitions, Mergers, Takeovers

OpenAI Makes Surprise Media Acquisition Ahead of IPO. Why It Will Fail. -- Barrons.com

3 kwi 2026, 14:11 UTC

Market Talk
Major News Events

Oil Shock From War in Iran May Show Up In 2Q Job Growth Data -- Market Talk

3 kwi 2026, 12:56 UTC

Market Talk

Treasury Yields, Dollar Higher Following Robust March Hiring -- Market Talk

3 kwi 2026, 08:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3 kwi 2026, 08:01 UTC

Market Talk

Global Equities Roundup: Market Talk

3 kwi 2026, 08:01 UTC

Market Talk

Meituan's Profitability Likely to Improve This Year -- Market Talk

3 kwi 2026, 07:45 UTC

Market Talk

LG Electronics Could Post Above-Consensus 1Q Earnings -- Market Talk

3 kwi 2026, 06:17 UTC

Market Talk

Naver Likely to Post Below-Consensus 1Q Earnings -- Market Talk

3 kwi 2026, 06:17 UTC

Market Talk

Global Equities Roundup: Market Talk

3 kwi 2026, 04:33 UTC

Market Talk

China Merchants Port Earnings Likely to Recover This Year -- Market Talk

3 kwi 2026, 04:33 UTC

Market Talk

Global Equities Roundup: Market Talk

3 kwi 2026, 04:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

3 kwi 2026, 04:01 UTC

Market Talk

Posco Holdings 1Q Earnings Could Fall Short of Expectations -- Market Talk

3 kwi 2026, 02:01 UTC

Market Talk

India Consumer-Staple Companies Likely to Post Broadly Steady 4Q Results -- Market Talk

3 kwi 2026, 01:59 UTC

Market Talk

Sea's Shopee E-Commerce Platform Likely in Reinvestment Phase -- Market Talk

3 kwi 2026, 01:44 UTC

Market Talk

Samsung Likely to Report Record Quarterly Earnings in 2026 -- Market Talk

3 kwi 2026, 01:22 UTC

Market Talk

Dollar Could Hit 160 Yen in Thin Holiday Trading -- Market Talk

Peer Comparison

Price change

Maravai LifeSciences Holdings Inc (Class A) Forecast

Price Target

By TipRanks

39.37% upside

12 Months Forecast

Average 4 USD  39.37%

High 5 USD

Low 3 USD

Based on 6 Wall Street analysts offering 12 month price targets forMaravai LifeSciences Holdings Inc (Class A) - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

6 ratings

3

Buy

3

Hold

0

Sell

Technical Score

By Trading Central

2.02 / 2.115Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

No Evidence

Sentiment

By Acuity

166 / 349 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat